Overview

RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa

Status:
Active, not recruiting
Trial end date:
2035-04-24
Target enrollment:
Participant gender:
Summary
Currently enrolling a total of 12 patients for Phase 2a of the study: 6 patients must have VA of no-better-than hand motion in the study eye, and 6 patients must have VA in the study eye to range from no-worse-than count fingers to 20/200 vision.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Allergan
RetroSense Therapeutics